- Forbes•3 hours ago
Todd Hagopian recently identified five sub-sectors of Biotech poised for the best potential returns under President Trump. Today Todd gives us a deep dive into NASH (Nonalcoholic Steatohepatitis), the sub-sector that he is most excited about for 2017.
- Investor's Business Daily•5 hours ago
Gilead and AbbVie will benefit from Merck's decision to take a $2.9 billion impairment charge on a hepatitis C drug, Leerink says.
- Barrons.com•5 hours ago
As markets continue to rocket to new highs, investors may be wondering if there are any bargains left. Jefferies' Brian Abrahams and his team have some suggestions. While major indexes are bumping up against ...
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||69.89 x 1200|
|Ask||69.90 x 1800|
|Day's Range||69.05 - 70.07|
|52 Week Range||65.38 - 103.10|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||7.04|
|Dividend & Yield||2.08 (3.02%)|
|1y Target Est||N/A|